Loading...
Loading...
Bristol-Myers
Squibb Company
BMY and AbbVie
ABBV today announced updated efficacy and safety data from a small,
randomized Phase 2, open-label study in patients with previously-treated
multiple myeloma that evaluated two doses of the investigational
monoclonal antibody elotuzumab (10 mg/kg and 20 mg/kg) in combination
with lenalidomide and low-dose dexamethasone. In the 10 mg/kg arm
(N=36), which is the dose used in the ongoing Phase 3 trials, median
progression-free survival (PFS), or the time without disease
progression, was 33 months after a median follow-up of 20.8 months (95%
CI: 14.9-NA) and the objective response rate (ORR) was 92%. As
previously reported, median PFS was 18 months in the 20 mg/kg arm (N=37)
after a median follow-up
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in